Pluristem Therapeutics
Pluristem Therapeutics is an Israeli company engaged in the development of human placental adherent stromal cells for commercial use in disease treatment.[2] According to the company's website, it extracts adult stem cells exclusively from postnatal placentas.[3]
Pluristem was founded in 2001 by Shai Meretzki of the Technion, who made use of stem cell patents he had developed with colleagues from the Weizmann Institute of Science.[4][5] In 2003, the NASDAQ-listed shell company A1 Software acquired all shares and patents belonging to Pluristem and changed its name to Pluristem Life Systems.[6][7] In 2007 the name was changed again, this time to Pluristem Therapeutics Inc.[4] Pluristem's shares are traded on the NASDAQ exchange and the Tel Aviv Stock Exchange, as well as on the Frankfurt Stock Exchange.
Products
Pluristem is in the process of clinically testing the use of its PLX (PLacental eXpanded) cells to treat peripheral arterial disease (PAD).[8]
See also
References
- ^ "TASE Site – Profile". Tel Aviv Stock Exchange. 2011. http://www.tase.co.il/TASEEng/General/Company/companyDetails.htm?subDataType=0&companyId=001569&ShareId=01121730#SummaryLink. Retrieved 22 September 2011.
- ^ "Pluristem Therapeutics Inc (PSTI:NASDAQ CM)". Bloomberg Businessweek. http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=PSTI:US. Retrieved 22 September 2011. "The company engages in the development of a pipeline of products, which are derived from human placenta, a non-controversial, non-embryonic, and adult stromal cell source."
- ^ "Pluristem: Who we are". Pluristem. http://www.pluristem.com/index.php?option=com_content&view=article&id=6&Itemid=19. Retrieved 22 September 2011. "Pluristem has made the strategic decision to work only with adult stem cells, purified from the placenta after birth and, therefore, not subject to ethical or religious controversy."
- ^ a b "PSTI Company Profile". MarketWatch. http://www.marketwatch.com/investing/stock/psti/profile. Retrieved 22 September 2011.
- ^ Cohen, Omri (9 April 2008). "פלוריסטם דיווחה על הצלחת ניסוי בתרופה לטיפול בשבץ מוחי בעזרת תאי גזע - והמניה קפצה ב-150% [Pluristem reports success in clinical trial involving drug for treating stroke using stem cells - stock soars 150%]" (in Hebrew). Haaretz. http://www.haaretz.co.il/misc/1.1317395. Retrieved 22 September 2011. "מרצקי הקים את פלוריסטם על בסיס פטנטים שפיתח עם פרופ' דב ציפורי ופרופ' אבינועם כדורי ממכון ויצמן."
- ^ Ovadia, Avishay (2 July 2003). "Stem cell technology co Pluristem enters Wall Street by back door". Globes. http://archive.globes.co.il/searchgl/Stem%20cell%20technology%20co%20Pluristem%20enters%20Wall%20Street_h_hd_0L3KsDJOtN3SmCZ8pCYveT6ri.html. Retrieved 22 September 2011. "All the shares in the company have been purchased by a stock market shell by the name of A1 Software, which also recently bought all the patent and know-how rights on the technology of Dr. Shai Meretzki and others at the Technion and the Weizmann Institute relating to stem cell expansion."
- ^ "פלוריסיסטם הישראלית נכנסת לוול-סטריט בדלת האחורית: נרכשה על-ידי השלד הבורסאי [A1] Software [Israeli Pluristem enters Wall Street by back door: Acquired by shell company A1 Software]" (in Hebrew). Globes. 1 July 2011. http://www.globes.co.il/news/article.aspx?did=701943. Retrieved 22 September 2011.
- ^ "PSTI Profile". Yahoo! Finance. http://finance.yahoo.com/q/pr?s=psti. Retrieved 22 September 2011. "The company provides PLX-PAD that has completed Phase I clinical trials for people suffering from peripheral artery disease."
External links
Israeli companies traded on NASDAQ |
|
| Healthcare |
|
|
Communication &
Networks |
|
|
| Software |
|
|
| Electronics |
|
|
| Security & defense |
|
|
| Consumer goods |
|
|
| Conglomerates |
|
|
|
|
|